185 related articles for article (PubMed ID: 26100175)
1. Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study.
Ishimoto O; Sugawara S; Inoue A; Maemondo M; Nukiwa T
Respir Investig; 2015 Jul; 53(4):156-60. PubMed ID: 26100175
[TBL] [Abstract][Full Text] [Related]
2. Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer.
Schmittel A; Schulze K; Hütter G; Krebs P; Thiel E; Keilholz U
Onkologie; 2004 Jun; 27(3):280-4. PubMed ID: 15249718
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.
Briasoulis E; Golfinopoulos V; Karina M; Papakostas P; Pavlidis N; Fountzilas G
Anticancer Drugs; 2010 Sep; 21(8):785-9. PubMed ID: 20647930
[TBL] [Abstract][Full Text] [Related]
4. A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02.
Okishio K; Mio T; Kawahara M; Yoshioka H; Yanagihara K; Daimon T; Furuse K
Jpn J Clin Oncol; 2012 May; 42(5):387-93. PubMed ID: 22430871
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer.
Sato M; Ando M; Minami H; Ando Y; Ando M; Yamamoto M; Sakai S; Watanabe A; Ikeda T; Sekido Y; Saka H; Shimokata K; Hasegawa Y
Cancer Chemother Pharmacol; 2001 Dec; 48(6):481-7. PubMed ID: 11800029
[TBL] [Abstract][Full Text] [Related]
6. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer.
Chen G; Huynh M; Fehrenbacher L; West H; Lara PN; Yavorkovsky LL; Russin M; Goldstein D; Gandara D; Lau D
J Clin Oncol; 2009 Mar; 27(9):1401-4. PubMed ID: 19204194
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
Morikawa N; Inoue A; Sugawara S; Maemondo M; Harada T; Harada M; Fujita Y; Katoh T; Yokouchi H; Watanabe H; Usui K; Suzuki T; Sakakibara-Konishi J; Nagai H; Kanbe M; Nukiwa T
Lung Cancer; 2017 Sep; 111():38-42. PubMed ID: 28838395
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer.
Fukuda M; Soda H; Soejima Y; Fukuda M; Kinoshita A; Takatani H; Kasai T; Nagashima S; Kawabata S; Doi S; Kohno S; Oka M
Cancer Chemother Pharmacol; 2006 Nov; 58(5):601-6. PubMed ID: 16463061
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer.
Yoshimura A; Noro R; Miyanaga A; Mizutani H; Kosaihira S; Minegishi Y; Seike M; Hino M; Ando M; Nomura K; Okano T; Kobayashi K; Gemma A;
Anticancer Res; 2012 Oct; 32(10):4473-8. PubMed ID: 23060575
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer.
Fukuda M; Oka M; Soda H; Kinoshita A; Fukuda M; Nagashima S; Kuba M; Takatani H; Tsurutani J; Nakamura Y; Kasai T; Inoue Y; Soejima Y; Kohno S;
Cancer Chemother Pharmacol; 2004 Dec; 54(6):573-7. PubMed ID: 15365766
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.
Misumi Y; Okamoto H; Sasaki J; Masuda N; Ishii M; Shimokawa T; Hosomi Y; Okuma Y; Nagamata M; Ogura T; Kato T; Sata M; Otani S; Takakura A; Minato K; Miura Y; Yokoyama T; Takata S; Naoki K; Watanabe K
BMC Cancer; 2017 May; 17(1):377. PubMed ID: 28549414
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.
Socinski MA; Sandler AB; Israel VK; Gillenwater HH; Miller LL; Locker PK; Antonellini A; Elfring GL; Natale RB
Cancer; 2002 Oct; 95(7):1520-7. PubMed ID: 12237921
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
[TBL] [Abstract][Full Text] [Related]
15. A phase I/II trial of irinotecan plus amrubicin supported with G-CSF for extended small-cell lung cancer.
Harada T; Hamada A; Shimokawa M; Takayama K; Kudoh S; Maeno K; Saeki S; Miyawaki H; Moriyama A; Nakagawa K; Nakanishi Y
Jpn J Clin Oncol; 2014 Feb; 44(2):127-33. PubMed ID: 24379211
[TBL] [Abstract][Full Text] [Related]
16. A phase I clinical trial of irinotecan and carboplatin in patients with extensive stage small cell lung cancer.
Crabb SJ; Bradbury J; Nolan L; Selman D; Muthuramalingam SR; Cave J; Johnson PW; Ottensmeier C
Chemotherapy; 2012; 58(4):257-63. PubMed ID: 22907396
[TBL] [Abstract][Full Text] [Related]
17. Population-based maximum tolerated dose of irinotecan and carboplatin.
Wild CA; Wang SE; Gandara DR; Lara PN; Meyers FJ; Tanaka M; Houston J; Lauder J; Lau DH
Oncology (Williston Park); 2003 Jul; 17(7 Suppl 7):11-6. PubMed ID: 12886868
[TBL] [Abstract][Full Text] [Related]
18. Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.
Charpidou A; Tsagouli S; Tsimpoukis S; Vassias A; Makrilia N; Stratakos G; Gkiozos I; Syrigos K
Anticancer Drugs; 2010 Jul; 21(6):651-5. PubMed ID: 20386306
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer.
Hirose T; Horichi N; Ohmori T; Ogura K; Hosaka T; Ando K; Ishida H; Noguchi H; Adachi M
Lung Cancer; 2003 Jun; 40(3):333-8. PubMed ID: 12781433
[TBL] [Abstract][Full Text] [Related]
20. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
Socinski MA; Smit EF; Lorigan P; Konduri K; Reck M; Szczesna A; Blakely J; Serwatowski P; Karaseva NA; Ciuleanu T; Jassem J; Dediu M; Hong S; Visseren-Grul C; Hanauske AR; Obasaju CK; Guba SC; Thatcher N
J Clin Oncol; 2009 Oct; 27(28):4787-92. PubMed ID: 19720897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
